WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008100995) HUMANIZED ANTI-CD100 ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/100995    International Application No.:    PCT/US2008/053816
Publication Date: 21.08.2008 International Filing Date: 13.02.2008
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01), A61P 37/06 (2006.01)
Applicants: VACCINEX, INC. [US/US]; 1895 Mt. Hope Avenue Rochester, NY 14620 (US) (For All Designated States Except US).
SMITH, Ernest, S. [US/US]; (US) (For US Only).
FISHER, Terrence, L., Jr. [US/US]; (US) (For US Only).
ZAUDERER, Maurice [US/US]; (US) (For US Only)
Inventors: SMITH, Ernest, S.; (US).
FISHER, Terrence, L., Jr.; (US).
ZAUDERER, Maurice; (US)
Agent: SPRUILL, W., Murray; Alston & Bird LLP, Bank of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US)
Priority Data:
60/901,530 14.02.2007 US
Title (EN) HUMANIZED ANTI-CD100 ANTIBODIES
(FR) ANTICORPS HUMAINS ANTI-CD100
Abstract: front page image
(EN)Compositions and methods are provided for treating diseases associated with CD1OO, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD1OO antigen or a CD1OO antigen located on the surface of a human CD1OO-expressing cell, wherein the antibody has CD1OO blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.
(FR)L'invention concerne des compositions et des procédés de traitement de maladies associées avec CD100, notamment certains types de cancers, de maladies auto-immunes, de maladies inflammatoires, notamment les maladies inflammatoires du système nerveux central (CNS) et du système nerveux périphérique (PNS), des rejets de transplantation et de l'angiogenèse invasive. Les compositions comprennent des anticorps anti-CD100 capables de se lier à un antigène CD100 humain soluble ou un antigène CD100 situé sur la surface d'une cellule humaine exprimant CD100, ledit anticorps présentant une activité de blocage de CD100 qui est obtenue en disposant au moins un CDR ou FWR optimisé dans la région variable de l'anticorps. Les compositions comprennent également des fragments à liaison antigène, des variantes et des dérivés des anticorps monoclonaux, des lignées cellulaires produisant ces compositions d'anticorps et des molécules isolées d'acide nucléique codant pour les séquences d'acides aminés des anticorps. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps anti-CD100 selon l'invention ou leurs fragments à liaison antigène, leurs variantes ou leurs dérivés, dans un véhicule pharmaceutiquement acceptable, ainsi que des procédés d'utilisation de ces anticorps anti-CD100.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)